Raymond Debbane, Director at LEXICON PHARMACEUTICALS, INC. (LXRX), bought 103,042 shares at $2.46 ($278K) on 2019-09-13, disclosed to the SEC on 2019-09-17.
Open-market purchase of $278k LXRX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.46 | 8,869 | $22K | 7.9% |
| 2 | $2.47 | 400 | $988 | 0.4% |
| 3 | $2.60 | 3,990 | $10K | 3.7% |
| 4 | $2.61 | 5,795 | $15K | 5.4% |
| 5 | $2.62 | 3,110 | $8K | 2.9% |
| 6 | $2.63 | 4,800 |
| $13K |
| 4.5% |
| 7 | $2.64 | 2,100 | $6K | 2.0% |
| 8 | $2.66 | 1,100 | $3K | 1.1% |
| 9 | $2.67 | 4,600 | $12K | 4.4% |
| 10 | $2.68 | 1,300 | $3K | 1.3% |
| 11 | $2.69 | 500 | $1K | 0.5% |
| 12 | $2.70 | 400 | $1K | 0.4% |
| 13 | $2.71 | 6,443 | $17K | 6.3% |
| 14 | $2.72 | 8,082 | $22K | 7.9% |
| 15 | $2.73 | 11,100 | $30K | 10.9% |
| 16 | $2.74 | 1,900 | $5K | 1.9% |
| 17 | $2.75 | 6,853 | $19K | 6.8% |
| 18 | $2.76 | 4,500 | $12K | 4.5% |
| 19 | $2.77 | 12,400 | $34K | 12.4% |
| 20 | $2.78 | 3,900 | $11K | 3.9% |
| 21 | $2.79 | 7,500 | $21K | 7.5% |
| 22 | $2.80 | 3,400 | $10K | 3.4% |
| Total | $2.69 avg | 103,042 | $278K | 100% |
| Filing → |
| LXRX | BUY | 2026-02-23 | $220K | — | Filing → |
| LXRX | BUY | 2026-02-18 | $353K | — | Filing → |
| LXRX | BUY | 2023-10-12 | $2.2M | — | Filing → |